NasdaqGS - Nasdaq Real Time Price USD

Centessa Pharmaceuticals plc (CNTA)

13.20

+0.94

+(7.67%)

At close: May 20 at 4:00:01 PM EDT

13.20

0.00

(0.00%)

After hours: May 20 at 4:31:54 PM EDT

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025Fireside Chat: 11:40 AM ET Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: June 10, 2025Fire

GlobeNewswire yesterday

CNTA
+7.67%
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clini

GlobeNewswire 6 days ago

CNTA
+7.67%
Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

The major averages were sharply higher near noon amid increased optimism around trade, as well as a decrease in U.S. initial jobless claims for the week ended May 3. President Trump announced a new trade deal with Great Britain, has said the U.S. intends to “make a deal with Europe,” and appears open to lowering tariffs on China after talks with the country this weekend. In central bank news, the Bank of England lowered its Bank Rate just a day after the U.S. Federal Reserve kept the federal fun

TipRanks 11 days ago

TSLA

CVNA

SHOP
Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]

Insider Monkey 15 days ago

CNTA
+7.67%
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in

GlobeNewswire last month

CNTA
+7.67%
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a

GlobeNewswire 2 months ago

CNTA
+7.67%
Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. Driven […]

Insider Monkey 4 months ago

CNTA
+7.67%
Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?

We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against the other growth stocks. AI is the Most Defining Theme of 2025, Says Expert Most experts agree that the AI wave is […]

Insider Monkey 4 months ago

CNTA
+7.67%
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. “Centessa is ra

GlobeNewswire 4 months ago

CNTA
+7.67%
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Key Insights Centessa Pharmaceuticals' estimated fair value is US$23.94 based on 2 Stage Free Cash Flow to Equity...

Simply Wall St. 4 months ago

CNTA
+7.67%
Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?

We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look at where Centessa Pharmaceuticals PLC (NASDAQ:CNTA) stands against the other stocks that jumped yesterday. Broader indices haven’t been performing very well since the Fed’s not so surprise revelation about the number of expected […]

Insider Monkey 4 months ago

CNTA
+7.67%
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.

BioPharma Dive 6 months ago

AMGN

AZN

NVS
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of Phase 1 data planned for medical congress in Q2 2025Initiated Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH; Phase 2a data across all three indications ex

GlobeNewswire 6 months ago

CNTA
+7.67%
Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech

We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are going to take a look at where Centessa Pharmaceuticals plc (NASDAQ:CNTA) stands against other small cap stocks with high potential. As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for interest […]

Insider Monkey 7 months ago

CNTA
+7.67%
Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at where Centessa Pharmaceuticals Plc (NASDAQ:CNTA) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, […]

Insider Monkey 7 months ago

CNTA
+7.67%
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders BOSTON and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today shared new preclinical data from non-huma

GlobeNewswire 7 months ago

CNTA
+7.67%
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expect

GlobeNewswire 8 months ago

CNTA
+7.67%
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day o

GlobeNewswire 8 months ago

CNTA
+7.67%
Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity

Centessa has a potential blockbuster narcolepsy treatment on its hands, an analyst said Tuesday. But the biotech stock reversed into the red.

Investor's Business Daily 8 months ago

CNTA
+7.67%
Top Midday Gainers

Top Midday Gainers

PREMIUM
MT Newswires 8 months ago

BKYI

CNTA
+7.67%

Performance Overview

Return	CNTA	MSCI WORLD (^990100-USD-STRD)
YTD	-19.27%	+4.54%
1-Year	+51.38%	+11.39%
3-Year	+190.11%	+45.94%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?

Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech

Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity

Top Midday Gainers

Performance Overview